肺动脉高压治疗药物新靶点的研究进展  

Research progress in new drug targets for the treatment of pulmonary hypertension

作　　者：李昱辰 李欣玫 吴凡 李特 LI Yu-chen;LI Xin-mei;WU Fan;LI Te(College of Pharmacy,Dali University,Dali Yunnan 671000;Department of Pharmacy,Yunnan Fuwai Cardiovascular Hospital,Kunming 650102)

机构地区：[1]大理大学药学院,云南大理671000 [2]云南省阜外心血管病医院药剂科,昆明650102

出　　处：《中南药学》2024年第1期154-159,共6页Central South Pharmacy

基　　金：云南省科技厅昆明医科大学联合专项(No.202201AY070001-210)。

摘　　要：肺动脉高压是一种复杂的心肺血管疾病,由于极高的致死率、致残率,一度被称为心血管领域的“恶性肿瘤”。目前,已上市肺动脉高压靶向药物在我国的广泛应用极大地提高了患者的生存率,然而,现有药物仍存一定的局限性,如疗效欠佳、不良反应严重等。近年来,随着对肺动脉高压发病机制研究的不断深入,越来越多的新靶点和新通路的发现为治疗肺动脉高压提供了更多的可能。TLR3激动剂Poly(I∶C)、STAT3信号通路的Corosolic acid等都已经进入临床试验阶段,有望填补现有靶向药物治疗的不足。与此同时,许多药物(如布洛芬、左西孟旦等)也有望成为肺动脉高压的靶点药物。本文主要总结了肺动脉高压新靶点治疗药物的研究现况,以期为今后肺动脉高压的研究和靶向治疗提供理论依据。Pulmonary hypertension(PH) is a complex cardiovascular disease with high mortality and disability rates.The utilization of PH-targeted drugs in China has enhanced patient survival rate.However,these drugs still possess limitations,such as low efficacy and obvious side effects.Recent research on the cause of PH has led to the discovery of new targets and pathways,offering hope for more treatment options.Clinical trials are underway for TLR3 agonist Poly(I∶ C) and Corosolic acid,which target the STAT3 signaling pathway.These treatments may overcome the limitations of existing medications.Additionally,drugs used in other fields,such as ibuprofen and levosimendan,have shown potential as therapies for PH.This article reviewed current research on new target drugs to lay the groundwork for future research and development of therapeutic targets for PH.

关 键 词：肺动脉高压 靶向药物 药物治疗 

分 类 号：R96[医药卫生—药理学]